Legend: Boston Convention & Exhibition Center = CC, Westin Boston Waterfront = W, Seaport Boston Hotel = S
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 605 * | Thu, 8/7/2014, 8:30 AM - 10:20 AM | CC-254A | |
| Adaptive Designs for Clinical Trials and Observational Studies — Contributed Papers | |||
| Biopharmaceutical Section | |||
| Chair(s): Eva Miller, Quality Data Services | |||
| 8:35 AM | Interim Sample Size Recalculation for Observational Studies — Sergey Tarima, Medical College of Wisconsin ; Peng He, Medical College of Wisconsin ; Tao Wang, Medical College of Wisconsin ; Aniko Szabo, Medical College of Wisconsin | ||
| 8:50 AM | Case Study: Application of Adaptive Enrichment Design with Co-Primary Endpoints in the Command Clinical Trial for Treatment of Mesothelioma — Robin Bliss, Veristat ; John Balser, Veristat ; Joanna Horobin, Verastem ; Mitchell Keegan, Verastem | ||
| 9:05 AM | An Adaptive Group-Sequential Test Without Predetermination of Total and Group Sample Sizes — Kosuke Kashiwabara, University of Tokyo ; Yutaka Matsuyama, University of Tokyo | ||
| 9:20 AM | Two-Stage Adaptive-Optimal Design with Fixed First-Stage Sample Size — Nancy Flournoy, University of Missouri ; Adam Lane, Cincinnati Children's Hospital Medical Center | ||
| 9:35 AM | Effect of Sample Size Re-Estimation in Adaptive Clinical Trials for Alzheimer's Disease and MCL — Guoqiao Wang, University of Alabama at Birmingham ; Richard Kennedy, University of Alabama at Birmingham ; Lon Schneider, University of Southern California Keck School of Medicine ; Gary Cutter, University of Alabama at Birmingham | ||
| 9:50 AM | Design Considerations in Phase IIa and IIb for a Symptomatic Alzheimer's Treatment — Christopher Assaid, Merck ; James Kost, Merck ; Jang-Ho Cha, Merck ; Ying Zhang, Merck | ||
| 10:05 AM | Design Optimizations and Implementation for Adaptive Clinical Trials: A Case Study for Cancer — Qiming Liao, GlaxoSmithKline | ||
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.